| ESR Vasculitis Day | ||
| 14:00 | Registration | |
| 14:45 – 15:15 | Welcome Coffee Reception | |
| 15:15 – 17:30 | Track A Moderators: Dr. Shamma Al Nokhatha and Dr. Fahad Fazal | |
| 15:15 – 15:45 | Behçet’s Disease: Navigating the Many Faces of a Complex Disorder | Dr. Ibrahim Almaghlouth |
| 15:45 – 16:15 | Emerging Insights in Takayasu Arteritis | Prof. David Saadoun |
| 16:15 – 16:45 | Giant Cell Arteritis: Evolving Paradigms in Diagnosis and Treatment | Prof. Aladdin Mohammad |
| 16:45 – 17:15 | Vessels in Flame: Targeting Complement for Precision Medicine in ANCA-associated Vasculitis | Prof. Björn Tampe |
| 17:15 – 17:30 | Q&A | |
| 17:30 – 17:45 | Coffee Break | |
| 15:15 – 17:30 | Track B Moderator: Dr. Mumtaz Khan | |
| 17:45 – 18:15 | The Invisible Inflammation: Uncovering CNS Vasculitis & Cryoglobulinemia | Prof. David Saadoun |
| 18:15 – 18:45 | MRI in CNS Small Vessel Vasculitis and Mimics | Dr. Iftikhar Ahmad |
| 18:45 – 19:15 | ANCA Vasculitis in 2025: Evolving Evidence and Emerging Therapies | Prof. Aladdin Mohammad |
| 19:15 – 19:45 | Q&A | |
| 19:45 – 20:15 | Industry Symposium by Vifor | |
Main Conference Day 1
| 07:30 – 15:00 | Registration | |
| 08:30 – 09:50 | Session 1: CAR T & Artificial Intelligence
Moderators: Dr. Najla Aljaberi & Dr. Tahir Khan |
|
| 08:30 – 08:50 | Keynote Lecture: Adopting New Artificial Intelligence (AI) Trends to Reshape Rheumatology Practice | Dr. Thomas Hügle |
| 08:50 – 09:20 | Making Sense of CAR T in Autoimmune Conditions | Dr. Chris Wincup |
| 09:20 – 09:40 | CAR T in Lupus – UAE Experience | Dr. Tahir Khan |
| 09:40 – 09:50 | Q&A & Certificates | |
| 09:50 – 10:10 | Opening Ceremony | |
| 10:10 – 10:40 | Industry Symposium by Novartis | |
| 10:40 – 10:55 | Coffee Break | |
| 10:55 – 12:25 | Session 2: WIN: What is New? | |
| 10:55 – 11:20 | Everything you Need to Know About GLP-1 Receptor Agonists and SGLT-2 Inhibitors | Dr. Elamin Abdelgadir |
| 11:20 – 11:45 | Bridging Gaps in JAKi Use Beyond Arthritis | Dr. Daniel Furst |
| 11:45 – 11:55 | Q&A & Certificates | |
| 11:55 – 12:25 | Industry Symposium by Pfizer | |
| 12:25 – 13:40 | Lunch | |
| 13:30 – 16:25 | Session 3: Systemic Lupus Erythematosus (SLE) / Antiphospholipid Syndrome (APS)
Moderator: Dr. Samar Al Emadi |
|
| 13:30 – 13:50 | Lupus Nephris Under the Lens: What’s New? What’s Next? | Dr. Oseme Etome |
| 13:50 – 14:10 | Pitfalls of the 2023 ACR/EULAR Antiphospholipid Syndrome (APS) Classification Criteria | Prof. Munther Khamashta |
| 14:10 – 14:50 | Decoding Systemic Lupus Erythematosus (SLE) / Antiphospholipid Syndrome (APS) in Pregnancy | Dr. Oseme Etome |
| 14:50 – 15:00 | Q&A & Certificates | |
| 15:00 – 15:30 | Industry Symposium by AbbVie | |
| 15:30 – 15:45 | Coffee Break | |
| 15:45 – 16:15 | Industry Symposium by Novartis | |
| 16:15 – 17:25 | Session 4: Rheumatoid Arthritis (RA)
Moderators: Dr. Hanan Al Rayes & Dr. Nizar Abdulateef |
|
| 16:15 – 16:45 | Cracking the Code of Difficult-to-Treat RA | Dr. Daniel Furst |
| 16:45 – 17:15 | Infection in Rheumatic Conditions: Use of immunomodulators in HIV infection | Dr. Aqeel Salem |
| 17:15 – 17:25 | Q&A & Certificates | |
| 17:25 – 18:30 | Session 5: Neoplasia and Rheumatology
Moderator: Dr. Tariq Aslam |
|
| 17:25 – 17:50 | Check it Out! What is New in Check Point Inhibitors in Rheumatology | Dr. Chris Wincup |
| 17:50 – 18:20 | DMARDs and Malignancy. Cancer Screening, EULAR Guidance and Beyond | Dr. Ahmed Zayat |
| 18:20 – 18:30 | Q&A & Certificates | |
| 07:30 – 15:00 | Registration | |
| 09:50 – 10:00 | Welcome Remarks | Dr. Bashayer Al Nuaimi |
| 10:00 – 11:45 | Pediatric Session 1 | |
| 10:00 – 10:35 | Monogenic Lupus: Insights into Clinical and Genetic Complexity | Dr. Sulaiman Almayouf |
| 10:35 – 11:10 | Approach to variant of unknown significance interpretation in SLE | Dr. Adnan AlAli |
| 11:10 – 11:45 | Atypical Presentations of Juvenile SLE | Dr. Reem Abdawani |
| 11:45 – 12:00 | Coffee Break | |
| 12:00 – 13:45 | Pediatric Session 2 | |
| 12:00 – 12:35 | Vasculitis in Children: Diagnosis, Management, and Long-Term Outcomes | Dr. Buthaina Al Athba |
| 12:35 – 13:10 | Optimizing the Transition from Pediatric to Adult Care: An Expert Opinion | Dr. Elsadeg Sharif |
| 13:10 – 13:45 | Targeting the JAK–STAT Pathway in Monogenic Interferonopathies: Clinical Advances and Challenges | Dr. Shima Kamal |
| 12:35 – 14:45 | Lunch | |
END OF DAY | ||
Main Conference Day 2
| 07:30 – 15:00 | Registration | |
| 08:30 – 10:25 | Session 6: How to Treat? HOT
Moderator: Dr. Humaid Al Wahshi |
|
| 08:30 – 08:55 | Osteoporosis in Males and Young Adults | Dr. Asma Aljaberi |
| 08:55 – 09:20 | Sequential Therapy in Osteoporosis | Dr. Mustafa Al Izzi |
| 09:20 – 09:45 | Sjögren’s – Sicca Symptoms to Sjögren’s | Dr. Thomas Hügle |
| 09:45 – 09:55 | Q&A & Certificates | |
| 09:55 – 10:25 | Industry Symposium by Lilly | |
| 10:25 – 10:45 | Coffee Break | |
| 10:45 – 11:15 | Industry Symposium by Novartis | |
| 11:15 – 12:15 | Session 7: How to Treat? HOT
Moderators: Dr. Amel Ginawi & Dr. Saadeya Naji |
|
| 11:15 – 11:40 | EULAR /PReS recommendation for the management of Still’s disease | Dr. Fatemah Baron |
| 11:40 – 12:05 | Connective Tissue Disease-associated Interstitial Lung Disease (CTD-ILD) | Dr. Mira Merashli |
| 12:05 – 12:15 | Q&A & Certificates | |
| 12:15 – 13:20 | Lunch | |
| 13:20 – 14:35 | Session 8: Metabolic Diseases
Moderator: Dr. Ahlam Al Marzooqi |
|
| 13:20 – 14:00 | Asymptomatic Hyperuricemia – To Treat or Not to Treat. A Debate | Dr. Francis Kynaston-Pearson Dr. Elhadi Eltayeb Abbas |
| 14:00 – 14:25 | DMARDs Induced Hepatic Stress: Navigating fatty liver disease and Hepatitis B,C infection | Dr. Saeed AlMarzooqi |
| 14:25 – 14:35 | Q&A & Certificates | |
| 14:35 – 14:50 | Coffee Break | |
| 14:50 – 15:50 | Session 9: Spondyloarthritis (SpA) | |
| 14:50 – 15:15 | Through the Eye of Inflammation: Uveitis in Rheumatology Practice | Dr. Aniruddha Agarwal |
| 15:15 – 15:40 | The Art and Science of Rheumatology: Bridging Evidence and Experience in D2T SpA | Dr. Asal Adnan |
| 15:40 – 15:50 | Q&A & Certificates | |
| 15:40 – 15:50 | Closing | |
*Disclaimer: Preliminary Agenda as of 28 October 2025, subject to potential modifications without prior notification.